Exact Sciences Corp(EXAS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.1 | Insider Own | 1.59% | Shs Outstand | 190.8M | Perf Week | - |
| Market Cap | 20.03B | Forward P/E | 125.64 | EPS next Y | 1889.27% | Insider Trans | -0.84% | Shs Float | 187.8M | Perf Month | 1.49% |
| Enterprise Value | 21.60B | PEG | - | EPS next Q | -0.19 | Inst Own | 85.48% | Short Float | 4.17% | Perf Quarter | 2.95% |
| Income | -0.21B | P/S | 6.17 | EPS this Y | 95.76% | Inst Trans | -6.8% | Short Ratio | 3.07 | Perf Half Y | 91.76% |
| Sales | 3.25B | P/B | 8.34 | EPS next 5Y | - | ROA | -3.39% | Short Interest | 7.84M | Perf YTD | 3.3% |
| Book/sh | 12.58 | P/C | 20.76 | EPS past 3/5Y | 32.2% 27.36% | ROE | -8.66% | 52W High | -0.07% ($104.98) | Perf Year | 136.92% |
| Cash/sh | 5.05 | P/FCF | 56.13 | Sales past 3/5Y | 15.92% 16.84% | ROIC | -4.25% | 52W Low | 170.3% ($38.81) | Perf 3Y | 65.37% |
| Dividend Est. | - | EV/EBITDA | 327.71 | EPS Y/Y TTM | 80.14% | Gross Margin | 69.69% | Volatility(W/M) | 0.23% 0.28% | Perf 5Y | -21.51% |
| Dividend TTM | - | EV/Sales | 6.65 | Sales Y/Y TTM | 17.69% | Oper. Margin | -4.79% | ATR (14) | 0.37 | Perf 10Y | 1570.54% |
| Dividend Ex-Date | - | Quick Ratio | 2.17 | EPS Q/Q | 90.29% | Profit Margin | -6.4% | RSI (14) | 76.4 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.43 | Sales Q/Q | 23.12% | SMA20 | 1.29% ($103.57) | Beta | 1.42 | Target Price | $105 |
| Payout | - | Debt/Eq | 1.06 | Earnings | 2026/2/13 | SMA50 | 1.83% ($103.02) | Rel Volume | 0 | Prev Close | $104.91 |
| Employees | 7200 | LT Debt/Eq | 1.04 | EPS/Sales Surpr. | -317.05% 2.03% | SMA200 | 41.21% ($74.29) | Avg Volume(3M) | 2.55M | Price | $104.91 |
| IPO | 2001/1/31 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
🔬 This is a US-based cancer diagnostics company whose core focus is early-detection screening for colorectal cancer and multi-cancer testing. It has established a strong position in the healthcare diagnostics field with its Cologuard colorectal cancer screening test and the Oncotype DX precision oncology test, and is expanding its business through a multi-cancer early-detection platform (CancerGuard).
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
EXAS has a sound balance sheet but weak earning power
Of every $100 in sales, $4.79 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +95.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $617. Peers typically go for $203.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -21.5%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 85.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #13 of 45 in the industry
Based on market cap of $20B.
FAQ
What kind of company is EXAS?
EXAS belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of EXAS?
The market cap of EXAS is approximately $20.0B, ranking 584 within its sector.
What is the 52-week high and low for EXAS?
EXAS has recorded a 52-week high of $104.98 and a low of $38.81.
